Merrimack Pharm (MACK) Reports Q3 Loss of $1.81

Merrimack Pharm (NASDAQ: MACK) reported Q3 EPS of ($1.81), versus ($0.25) reported last year. Revenue for the quarter came in at $11.3 million, versus $8.6 million reported last year.

For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue